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Abstract: After primary tumor treatment, 30% of patients with
malignant melanoma develop metastatic disease, usually associated
with a poor prognosis. Effective chemotherapeutic regimens for
metastatic melanoma are not currently available. Surgical treatment
of pulmonary metastases remains controversial because of the dis-
mal survival rates reported in several studies. However, for patients
with good performance status, long disease-free interval, limited
metastatic disease, and less aggressive tumor biology, it remains an
option. The authors have analyzed their experience in 26 patients
operated on between 2000 and 2008 alongside a review of the large
series in the literature.
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After primary tumor treatment, 30% of patients with ma-lignant melanoma develop metastatic disease, usually
associated with a poor prognosis. Despite the impressive
therapeutic advances that have been made during the last
three decades for early stage melanoma, prognosis of meta-
static disease remains poor. Chemotherapy and biotherapy
have demonstrated only partial clinical response. The regi-
mens, either alone or in combination, are usually difficult to
tolerate and dramatically impact on patients’ quality of life
and provide little, if any, proven survival benefit.1 In contrast,
surgical resection of pulmonary metastases may be consid-
ered a safe and effective approach. In highly selected cases,
metastasectomy may be followed by long-term survival. In
the absence of better systemic treatments, we as thoracic
surgeons are prevailed on to offer our help to these patients.
We sought to review our practice and results in the light of
the evidence from large datasets.
OUR INSTITUTIONAL EXPERIENCE
We present our experience, which we believe to be
representative of the approach undertaken by a dedicated
high-volume thoracic surgical team with experience of pul-
monary metastasectomy for a range of primary diagnoses.
From January 2000 to December 2008, 26 patients with stage
IV melanoma underwent surgical resection of lung metastasis
(mean age 62 years, range 28–79 years) at the Department of
Thoracic Surgery of University of Torino (Table 1).
There were 14 men and 12 women. Three patients
underwent a repeat complete metastasectomy. Eligibility cri-
teria for curative resection included complete resection of the
primary tumor, no evidence of extrapulmonary metastases,
resectable pulmonary metastasis, and predicted postresection
lung volumes compatible with the anticipated resection.
Complete tumor resection was confirmed histologically in all
cases. A retrospective study was performed to analyze clin-
ical outcome and survival time. In 17 patients (65%), the lung
represented the first metastatic localization, and in nine pa-
tients (35%), pulmonary metastases developed after meta-
static spread to extrapulmonary sites. Fourteen patients pre-
sented with a single pulmonary metastases, five patients had
two lesions, and seven patients had three or more lung
metastases. All patients in the study received adjuvant or
neoadjuvant systemic therapy. The median time interval from
surgery for the primary tumor to resection of lung metastases
was 36 months (range 12–240 months). In all cases, pulmo-
nary metastases were discovered by chest radiography during
a routine follow-up program. The mean tumor size was 15
mm ranging from 10 to 55 mm. An anatomic resection
(lobectomy) was required in three patients, and the other 23
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TABLE 1. Demographic and Clinical Characteristics of
Patients (n  26)
Gender (males/females) 14/12
Mean age (yr) 62 (range 28–79)
40 4
40–60 8
60 14
Lung localization
Right lung 16
Left lung 8
Bilateral 2
No. of metastases
1 Node 14
2 Nodes 5
2 Nodes 7
Type of resection
Wedge resection 23
Lobectomy 3
Median disease-free interval 36 mo
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(88%) patients were treated with a wedge resection. There
was no postoperative mortality.
Survival time was calculated from the date of surgical
resection to the date of death or the last follow-up. The 1-, 3-,
and 4-year survival rates are 72, 36, and 23%, respectively.
Actuarial survival curves were calculated by the Kaplan-
Meier method. Cox regression analysis was performed to
identify independently predictive prognostic factors. We
looked for the effect of age, sex, the number of metastases,
and the interval from primary melanoma resection to lung
metastasectomy on survival but only the female gender was
independently a favorable factor for survival (P  0.05;
Figures 1–5). However, given the relatively small dataset and
prior selection for these factors, failure to show effects of the
number of metastases and the time interval may well be
simply a matter of insufficient data to show a relationship.
REVIEW OF EVIDENCE FROM LARGE SERIES
A formal search of the literature reveals many case
reports of unusual manifestations and some small series. We
selected three case series for presentation in our evidence
FIGURE 1. Overall survival.
FIGURE 2. Survival and gender.
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table on the basis of their size, some information concerning
the size of the denominator from which the cases were
selected, and the applicability of the data and its analysis to
our clinical context1–3 (Table 2).
Tafra et al.2 reviewed a 22-year melanoma database of
6100 patients. Of 984 patients with pulmonary metastases,
106 underwent surgical treatment; the remaining 878 cases
were treated with immunotherapy, chemotherapy, radiother-
apy, or a combination. The 1-, 3-, and 5-year survival rates
for surgical patients were 77, 37, and 27% compared with 32,
7, and 3% in nonsurgical patients, respectively. The highest
5-year survival rate (39%) occurred in patients with a single
metastatic lesion (Table 3).
Pastorino et al.3 reported melanoma outcomes within
the International Registry of Lung Metastasectomy in 328
patients who underwent lung metastasectomy in the period
FIGURE 3. Survival and age.
FIGURE 4. Survival and number
of nodes.
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1945 to 1995. After complete surgical resection, the 5- and
10-year survival rates were 22 and 16%, respectively. A
disease-free interval shorter than 36 months and the presence
of multiple metastases were independent unfavorable prog-
nostic factors. There were no long-term survivors after in-
complete resection.
The report of Harpole et al.4 in 1992 has been updated
with a recent report of 1720 patients with pulmonary metas-
tases from a database of 14,057 patients collected during
the period 1970 to 2004. From the large databases of all
melanoma cases, the 5-year survival rate for patients with
metastases was approximately 6%. Favorable predictors
for survival are given in Table 4. Given that pulmonary
metastasectomy features among them, it is not surprising
that patients and their oncologists seek the help of thoracic
surgeons.
Recently, Neuman et al.5 claimed 3-fold difference in
median survival with and without pulmonary metastasec-
tomy. They presented a series of 122 patients with stage IV
FIGURE 5. Survival and disease-
free interval (DFI).
TABLE 2. Data from Three Reports Including Pulmonary Metastasectomy for Melanoma
Study/Report Period
Melanoma Patients in
the Database/Registry
Pulmonary
Metastases
Pulmonary
Metastasectomy Operative Rate
5-yr
Survival Rate
10-yr
Survival Rate
Tafra et al.2 1971–1993 6100 984 106 11% 27%
Pastorino et al.3 1945–1995 328 22% 16%
Petersen et al.1 1970–2004 14,057 1720 298 17%
Where data were available, the total number of melanoma cases in the registry is given (Column 3), the number of patients with pulmonary metastases, the total number, and
the percentage that had metastasectomy are given in Columns 4–6.
TABLE 3. Univariate and Multivariate Analyses of Factors
Affecting Survival of Surgical Patients
Factor Univariate Multivariate
Tumor doubling time (60 vs. 60 d) 0.0005 0.002
Presence of extrapulmonary metastases 0.014 0.04
No. of lung metastases (1 vs. 1) 0.006 0.9
Complete vs. incomplete resection 0.09
Wedge resection vs. lobectomy 0.13
Disease-free interval (30 vs. 30 mo) 0.315
Data from Tafra et al.2
TABLE 4. Hazard Ratios for Factors Predictive of Overall
Survival in Patients with Pulmonary Metastases
Predictor
Hazard
Ratio
95% Confidence
Interval p
Nodular histologic type 1.1 1.01–1.3 0.033
No. of pulmonary metastases 2 1.2 1.04–1.4 0.012
Disease-free interval 1.5 1.3–1.7 0.001
Presence of extrathoracic
metastasis
1.7 1.6–1.9 0.001
Pulmonary metastasectomy 0.5 0.4–0.6 0.001
Reference category is disease-free interval longer than 5 yr.
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melanoma and pulmonary metastasis as the initial disease
site; median survival was 14 months. Of these, 26 (21%)
underwent metastasectomy, with a median survival of 40
months compared with 13 months in patients not selected for
surgical treatment. Clinical factors at the time of diagnosis of
stage IV melanoma independently predictive of survival were
a solitary pulmonary metastasis (P 0.0005) and the absence
of extrapulmonary disease (P  0.01).
Finally, Ollila et al.6 presented an experience of 129
patients undergoing complete or partial resection of lung
metastatic melanoma. They identified the tumor doubling
time (TDT) as the most significant preoperative prognostic
factor for patients undergoing pulmonary metastasectomy.
For TDT 60 days, neoadjuvant chemotherapy is recom-
mended. Their conclusion is that pulmonary metastasectomy
should not be attempted if TDT cannot be increased over 60
days by the systemic therapy.
DISCUSSION
When denominator data are available, it is first impor-
tant to note the high degree of selection for pulmonary
metastasectomy of patients with metastases, which is 11 and
17% (Table 2). That said, pro rata, it seems that pulmonary
metastasectomy is much more commonly performed in pa-
tients with melanoma than those with colorectal cancer where
the equivalent rate is of the order of 1 to 2%.7,8 Direct
comparison of outcomes in the selected patients with those
selected to not have surgery is clearly not appropriate. Naturally
correction must be applied, but adjustment can only be made for
known factors that have been recorded in the database. Many
factors go into the selection of patients for surgery, by them-
selves, and at primary, secondary, and tertiary care, which
cannot be captured. When the degree of selection is of the order
of 1 in 5–10, it would not be surprising if there is more in the
expert selection that is performed than can be captured by the
statistical techniques employed.
There is also some concern about the selective report-
ing of patients in whom complete resection was performed.1,3
The criteria on which we select future patients have to be
those which are available to clinicians at the time of
decision making. Reporting the outcomes on “intention to
treat” should include patients where, despite best inten-
tions, R0 resection was not achieved. That should be
included in the headline outcome data and is what future
patients need to know.
It is clear that all the factors associated with longer
survival in patients undergoing metastasectomy are also pre-
dictors of longer survival in the disease overall including
TDT. We still cannot be sure whether the selection of cases
with these features is the explanation for longer survival in
patients undergoing pulmonary metastasectomy.9 A consis-
tent feature is that complete removal of all disease versus
incomplete removal is associated with a significant difference
in survival10 cannot ignore the evidence that patients who
have presented with few lesions, usually a single metastasis,
may be long survivors after complete removal and will
continue to ask for surgery in the hope case that surgery will
have a beneficial effect on their survival. Conversely, there is
increasingly strong evidence of the factors that predict poor
survival after surgery, and so, we will want to continue being
highly selective.
RECOMMENDATIONS
Our conclusion for future practice is that pulmonary
metastases from malignant melanoma should be operated if
the patient meets the following criteria:
1. The primary site of melanoma is fully controlled.
2. There is a limited number of pulmonary metastases.
3. There is no evidence of extrapulmonary metastases in
computed tomography and positron emission tomogra-
phy-computed tomography scans.
4. A long disease-free interval has passed by between the
resection of the primary melanoma and the develop-
ment of pulmonary metastasis.
5. A presumably complete resection of the lung metastases
can be accomplished.
6. There is no clinical and imaging evidence of involve-
ment of intrathoracic lymph nodes.
7. A long TDT is identified.
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